A Phase 1 Study of SC-011 as a Single-Agent and in Combination with ABBV-181 in Subjects with Relapsed or Refractory Small Cell Lung Cancer

Grants and Contracts Details

StatusActive
Effective start/end date5/6/20 → 10/30/24

Funding

  • AbbVie Incorporated: $266,864.00